The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| COEP | +4.55% | -94.44% | -43.86% | -94% |
| S&P | +13.95% | +78.35% | +12.25% | +86% |
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
No news articles found for Coeptis Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $237.44K | 0.0% |
| Gross Profit | -$654.15K | -135.1% |
| Gross Margin | -275.50% | 0.0% |
| Market Cap | $84.16M | 1070.5% |
| Market Cap / Employee | $12.02M | 0.0% |
| Employees | 7 | 0.0% |
| Net Income | -$2,898.76K | -58.5% |
| EBITDA | -$2,171.26K | -16.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.91M | 331.5% |
| Accounts Receivable | $82.50K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $150.00K | -29.0% |
| Short Term Debt | $129.87K | -91.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -90.30% | 37.2% |
| Return On Invested Capital | -370.27% | -37.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,152.22K | -13.7% |
| Operating Free Cash Flow | -$2,152.22K | -13.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.20 | 3.75 | 3.90 | 11.69 | 1026.22% |
| Price to Sales | 457.97 | 109.70 | 165.37 | - | |
| Price to Tangible Book Value | 2.15 | 6.22 | 5.33 | 15.43 | -45.44% |
| Enterprise Value to EBITDA | -6.93 | -7.34 | -6.70 | -36.09 | 745.19% |
| Return on Equity | -226.6% | -197.2% | -171.6% | -127.3% | -38.01% |
| Total Debt | $1.40M | $2.04M | $1.33M | $279.87K | -84.23% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
